The association between gastroesophageal reflux disease and recurrent respiratory papillomatosis: A systematic review

Laryngoscope

Volumn 126, Issue 10, 2016, Pages 2330-2339

  San Giorgi, Michel R M ^a,b   Helder, Herman M ^a   Lindeman, Robbert Jan S ^a   de Bock, Geertruida H ^a,b   Dikkers, Frederik G ^a,b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Gastroesophageal reflux disease; recurrent respiratory papillomatosis

Indexed keywords

ARTICLE; DISEASE ASSOCIATION; DISEASE COURSE; DYSPLASIA; GASTROESOPHAGEAL REFLUX; HUMAN; INCIDENCE; LARYNX PAPILLOMATOSIS; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SCORING SYSTEM; SYSTEMATIC REVIEW; TUMOR RECURRENCE;

EID: 84990230988     PISSN: 0023852X     EISSN: 15314995     Source Type: Journal    
DOI: 10.1002/lary.25898     Document Type: Article

References (43)

1. Tjon Pian Gi RE, San Giorgi MR, Slagter-Menkema L, et al. Clinical course of recurrent respiratory papillomatosis: comparison between aggressiveness of human papillomavirus-6 and human papillomavirus-11. Head Neck 2015;37:1625–1632.
2. Sanchez GI, Jaramillo R, Cuello G, et al. Human papillomavirus genotype detection in recurrent respiratory papillomatosis (RRP) in colombia. Head Neck 2013;35:229–234.
3. Draganov P, Todorov S, Todorov I, Karchev T, Kalvatchev Z. Identification of HPV DNA in patients with juvenile-onset recurrent respiratory papillomatosis using SYBR green real-time PCR. Int J Pediatr Otorhinolaryngol 2006;70:469–473.
4. Gerein V, Rastorguev E, Gerein J, Draf W, Schirren J. Incidence, age at onset, and potential reasons of malignant transformation in recurrent respiratory papillomatosis patients: 20 years experience. Otolaryngol Head Neck Surg 2005;132:392–394.
5. Wiatrak BJ, Wiatrak DW, Broker TR, Lewis L. Recurrent respiratory papillomatosis: a longitudinal study comparing severity associated with human papilloma viral types 6 and 11 and other risk factors in a large pediatric population. Laryngoscope 2004;114(suppl 104):1–23.
6. Moore CE, Wiatrak BJ, McClatchey KD, et al. High-risk human papillomavirus types and squamous cell carcinoma in patients with respiratory papillomas. Otolaryngol Head Neck Surg 1999;120:698–705.
7. Gabbott M, Cossart YE, Kan A, Konopka M, Chan R, Rose BR. Human papillomavirus and host variables as predictors of clinical course in patients with juvenile-onset recurrent respiratory papillomatosis. J Clin Microbiol 1997;35:3098–3103.
8. Pou AM, Rimell FL, Jordan JA, et al. Adult respiratory papillomatosis: human papillomavirus type and viral coinfections as predictors of prognosis. Ann Otol Rhinol Laryngol 1995;104:758–762.
9. Stern PL, van der Burg SH, Hampson IN, et al. Therapy of human papillomavirus-related disease. Vaccine 2012;30(suppl 5):F71–F82.
10. Gallagher TQ, Derkay CS. Pharmacotherapy of recurrent respiratory papillomatosis: an expert opinion. Expert Opin Pharmacother 2009;10:645–655.
11. Powell J, Cocks HC. Mucosal changes in laryngopharyngeal reflux—prevalence, sensitivity, specificity and assessment. Laryngoscope 2013;123:985–991.
12. Coca-Pelaz A, Rodrigo JP, Paccagnella D, et al. Reflux and aerodigestive tract diseases. Eur Arch Otorhinolaryngol 2013;270:417–423.
13. Coca-Pelaz A, Rodrigo JP, Takes RP, et al. Relationship between reflux and laryngeal cancer. Head Neck 2013;35:1814–1818.
14. Hawkshaw MJ, Pebdani P, Sataloff RT. Reflux laryngitis: an update, 2009–2012. J Voice 2013;27:486–494.
15. Erickson E, Sivasankar M. Simulated reflux decreases vocal fold epithelial barrier resistance. Laryngoscope 2010;120:1569–1575.
16. Doorbar J, Quint W, Banks L, et al. The biology and life-cycle of human papillomaviruses. Vaccine 2012;30(suppl 5):F55–F70.
17. Doorbar J. Latent papillomavirus infections and their regulation. Curr Opin Virol 2013;3:416–421.
18. Goon P, Sonnex C, Jani P, Stanley M, Sudhoff H. Recurrent respiratory papillomatosis: an overview of current thinking and treatment. Eur Arch Otorhinolaryngol 2008;265:147–151.
19. Derkay CS, Wiatrak B. Recurrent respiratory papillomatosis: a review. Laryngoscope 2008;118:1236–1247.
20. Carifi M, Napolitano D, Morandi M, Dall'Olio D. Recurrent respiratory papillomatosis: current and future perspectives. Ther Clin Risk Manag 2015;11:731–738.
21. Venkatesan NN, Pine HS, Underbrink MP. Recurrent respiratory papillomatosis. Otolaryngol Clin North Am 2012;45:671–94, viii–ix.
22. Kramer B. Information retrieval: Literature searching in Today's information landscape. Hypothesis 2010;8:1–7.
23. NIH. Quality assessment tool for observational cohort and cross-sectional studies. Available at: https://www.nhlbi.nih.gov/health-pro/guidelines/in-develop/cardiovascular-risk-reduction/tools/cohort. Accessed May 28, 2015.
24. Lazrak A, Nazih N, Filali AA, Kzdri M. Laryngeal papillomatosis in adults: report on 4 cases. Rev Laryngol Otol Rhinol (Bord) 2004;125:107–112.
25. Maturo S, Hartnick CJ. Use of 532-nm pulsed potassium titanyl phosphate laser and adjuvant intralesional bevacizumab for aggressive respiratory papillomatosis in children: initial experience. Arch Otolaryngol Head Neck Surg 2010;136:561–565.
26. Davids T, Muller S, Wise JC, Johns MM 3rd, Klein A. Laryngeal papillomatosis associated dysplasia in the adult population: an update on prevalence and HPV subtyping. Ann Otol Rhinol Laryngol 2014;123:402–408.
27. Ruiz R, Achlatis S, Verma A, et al. Risk factors for adult-onset recurrent respiratory papillomatosis. Laryngoscope 2014;124:2338–2344.
28. McKenna M, Brodsky L. Extraesophageal acid reflux and recurrent respiratory papilloma in children. Int J Pediatr Otorhinolaryngol 2005;69:597–605.
29. Caballero M, Romero A, Gonzalez L, Gomez E. Reflujo gastroesofagico en papilomatosis respiratoria recurrente: incidencia e influencia en el curso clinico. Anales de Otorinolaryngologia Mexicana 2013;58:146–150.
30. Campisi P, Hawkes M, Simpson K, Canadian Juvenile Onset Recurrent Respiratory Papillomatosis Working Group. The epidemiology of juvenile onset recurrent respiratory papillomatosis derived from a population level national database. Laryngoscope 2010;120:1233–1245.
31. Rodier C, Lapointe A, Coutlee F, et al. Juvenile respiratory papillomatosis: Risk factors for severity. J Med Virol 2013;85:1447–1458.
32. Sajan JA, Kerschner JE, Merati AL, Osipov V, Szabo S, Blumin JH. Prevalence of dysplasia in juvenile-onset recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 2010;136:7–11.
33. Verguts MM, Genbrugge E, de Jong FI. Treatment results in adult-onset recurrent respiratory papillomatosis. B-ENT 2009;5:137–141.
34. Derkay CS, Hester RP, Burke B, Carron J, Lawson L. Analysis of a staging assessment system for prediction of surgical interval in recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol 2004;68:1493–1498.
35. Ilmarinen T, Nissila H, Rihkanen H, et al. Clinical features, health-related quality of life, and adult voice in juvenile-onset recurrent respiratory papillomatosis. Laryngoscope 2011;121:846–851.
36. Weinberger P, Robb P, Carlson H, Perakis H, McChesney J, Postma G. Predictors of clinically aggressive recurrent respiratory papillomatosis. Laryngoscope 2009;119:104.
37. Holland BW, Koufman JA, Postma GN, McGuirt WF Jr. Laryngopharyngeal reflux and laryngeal web formation in patients with pediatric recurrent respiratory papillomas. Laryngoscope 2002;112:1926–1929.
38. Ronkainen J, Agreus L. Epidemiology of reflux symptoms and GORD. Best Pract Res Clin Gastroenterol 2013;27:325–337.
39. Bouchard S, Lallier M, Yazbeck S, Bensoussan A. The otolaryngologic manifestations of gastroesophageal reflux: when is a pH study indicated? J Pediatr Surg 1999;34:1053–1056.
40. Pignatari SS, Liriano RY, Avelino MA, Testa JR, Fujita R, De Marco EK. Gastroesophageal reflux in patients with recurrent laryngeal papillomatosis. Braz J Otorhinolaryngol 2007;73:210–214.
41. Spechler SJ. Barrett esophagus and risk of esophageal cancer: clinical review. JAMA 2013;310:627–636.
42. FDA. Safety information on proton pump inhibitors. Available at: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm213259.htm. Accessed June 24, 2015.
43. Shah NH, LePendu P, Bauer-Mehren A, et al. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLoS One 2015;10:e0124653.